Thanks to next-generation sequencing, we have started to unravel the cancer genomic landscape of several major cancer entities that contributes to the pathogenesis and/or evolution of the disease. For the majority of cancer subtypes, a quite diverse and complex mutation pattern is observed, with a limited number of frequently mutated genes accompanied by a long tail of genes with low-frequency mutations. Some of these genes have already been implied to have diagnostic, prognostic/predictive and even therapeutic impact, while most mutations still require functional validation. In parallel, large efforts have been made to design novel strategies targeting key cellular pathways and processes, which in turn has led to introduction of targeted therapy in selected entities. However, there is still a gap-of-knowledge and urgent medical need how to combine the genetic information with risk-stratification and treatment algorithms in the individual patient, i.e., precision medicine. This symposium will exemplify large sequencing efforts carried out in different cancer types, including both solid tumors and hematological malignancies, which paved the way for the incorporation of next-generation sequencing-based approaches into clinical routine diagnostics and every-day patient care. The conference will encompass the rapidly evolving field of disease monitoring by ultra-sensitive sequencing of tumor-specific mutations, as well as introduce novel approaches and other omics technologies and functional studies that will aid future efforts in precision medicine. Finally, successful examples of how genomic findings have spurred development of targeted therapies will be presented. In summary, the symposium will bring together basic scientists, translational researchers and clinicians to meet and discuss a consorted action towards precision medicine in cancer.